Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 11, 2026, 5:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hepatobiliary Diseases Clear all
Terminated Phase 2 Interventional Results available

Carbamazepine in Severe Liver Disease Due to Alpha-1 Antitrypsin Deficiency

NCT01379469
View directory record Official record
Conditions
Alpha-1-antitrypsin Deficiency, Liver Cirrhosis
Interventions
Drug-Carbamazepine (Tegretol XR), Carbamazepine (Tegretol XR) Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
14 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
3
States / cities
St Louis, Missouri • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Jun 11, 2026, 5:32 AM EDT
Completed No phase listed Observational

Non-invasive Biomarkers of Fibrosis in Pediatric Liver Diseases

NCT01988753
View directory record Official record
Conditions
Viral Hepatitis, Liver Fibrosis, Liver Disease, Hepatitis B, Hepatitis C
Interventions
Not listed
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 17 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Jun 11, 2026, 5:32 AM EDT
Completed No phase listed Observational

Development and Assessment of The Polycystic Liver Disease Questionnaire (PLD-Q).

NCT02173080
View directory record Official record
Conditions
Polycystic Liver Disease
Interventions
PLD-Q
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
594 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jun 11, 2026, 5:32 AM EDT
Not listed Phase 1 Interventional

Mobilization of Stem Cells With G-CSF and Mozobil in Patients With End Stage Liver Disease

NCT01711073
View directory record Official record
Conditions
End Stage Liver DIsease
Interventions
Mobilization with G-CSF and Mozobil
Drug
Lead sponsor
Proteonomix, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Jun 11, 2026, 5:32 AM EDT
Completed Not applicable Interventional

Feasibility, Safety and Acceptability of a Mobile Health Delivered Exercise Training Program in Patients With Nonalcoholic Steatohepatitis

NCT06195943
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis, NASH, Exercise, Liver
Interventions
Exercise Intervention with use of El-Fit App
Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Jun 11, 2026, 5:32 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Combination SBRT With TACE for Unresectable Hepatocellular Carcinoma

NCT01020812
View directory record Official record
Conditions
Carcinoma, Hepatocellular, Hepatobiliary Neoplasm, Liver Carcinoma
Interventions
TACE, SBRT
Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 26, 2016 · Synced Jun 11, 2026, 5:32 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)

NCT02912260
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis
Interventions
MGL-3196, Placebo
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
26
States / cities
Dothan, Alabama • Tucson, Arizona • Coronado, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Jun 11, 2026, 5:32 AM EDT
Terminated Phase 2 Interventional Results available

Use of a Novel Drug in People With Non-alcoholic Steatohepatitis (NASH) or Non-alcoholic Fatty Liver Disease (NAFLD)

NCT02605616
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH)
Interventions
AZ compound, Placebo
Drug · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
21 Years to 75 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 29, 2024 · Synced Jun 11, 2026, 5:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Nonalcoholic Fatty Liver Disease and Atherosclerotic Risk in Children

NCT02383485
View directory record Official record
Conditions
Overweight and Obesity, Non-alcoholic Fatty Liver Disease
Interventions
Exercise, After-school program
Behavioral
Lead sponsor
Augusta University
Other
Eligibility
8 Years to 11 Years
Enrollment
175 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 8, 2015 · Synced Jun 11, 2026, 5:32 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Obesity on Proton Pump Inhibitors

NCT04248335
View directory record Official record
Conditions
Pediatric Obesity, NAFLD, GERD
Interventions
Lansoprazole, Pantoprazole, Midazolam
Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
6 Years to 21 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jun 11, 2026, 5:32 AM EDT
Completed Phase 3 Interventional Results available

Treatment of Thrombocytopenia in Patients With Chronic Liver DiseaseUndergoing an Elective Procedure

NCT01972529
View directory record Official record
Conditions
Thrombocytopenia Associated With Liver Disease
Interventions
avatrombopag (lower baseline platelet count), placebo (lower baseline platelet count), avatrombopag (higher baseline platelet count), placebo (higher baseline platelet count)
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
21
States / cities
Lancaster, California • Long Beach, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2018 · Synced Jun 11, 2026, 5:32 AM EDT
Not listed No phase listed Observational

Development of Kinetic Biomarkers of Liver Fibrosis Measuring NAFLD

NCT02124577
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Jun 11, 2026, 5:32 AM EDT
Recruiting Phase 2 Interventional

A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition

NCT05519475
View directory record Official record
Conditions
Metabolic Dysfunction-Associated SteatoHepatitis (MASH)
Interventions
ALN-HSD, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
61
States / cities
Chandler, Arizona • Flagstaff, Arizona • Peoria, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Jun 11, 2026, 5:32 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

NCT03449446
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
SEL, FIR, CILO, Placebo to match FIR, Placebo to match CILO, Placebo to match SEL
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
81
States / cities
Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 62 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Jun 11, 2026, 5:32 AM EDT
Terminated Phase 4 Interventional Results available

DAA Treatment in Donor HCV-positive to Recipient HCV-negative Liver Transplant

NCT03208127
View directory record Official record
Conditions
End Stage Liver Disease, Hepatitis C
Interventions
Treatment with Direct Acting Antiviral tablet
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Jun 11, 2026, 5:32 AM EDT
Recruiting Phase 2 Interventional

Study of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced Fibrosis

NCT07610837
View directory record Official record
Conditions
Liver Fibrosis, Hepatic Cirrhosis
Interventions
AZD2389, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
19
States / cities
Chandler, Arizona • Jupiter, Florida • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Jun 11, 2026, 5:32 AM EDT
Completed Not applicable Interventional

Non-Pharmaceutical Intervention for Cirrhotic Cramps Reduction: The NICCles Trial

NCT04650295
View directory record Official record
Conditions
Cirrhosis, Muscle Cramp, Ascites
Interventions
Household Remedy, Tap water
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Jun 11, 2026, 5:32 AM EDT
Terminated Phase 4 Interventional Results available

Pediatric Study to Evaluate Risk of Developing Essential Fatty Acid Deficiency When Receiving Clinolipid or Standard-of-Care Lipid Emulsion

NCT02476994
View directory record Official record
Conditions
Essential Fatty Acid Deficiency (EFAD)
Interventions
Clinolipid, Intralipid
Drug
Lead sponsor
Baxter Healthcare Corporation
Industry
Eligibility
Up to 17 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
Park Ridge, Illinois • Indianapolis, Indiana • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Jun 11, 2026, 5:32 AM EDT
Recruiting Phase 2 Interventional

Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States

NCT05832229
View directory record Official record
Conditions
Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B, Cirrhosis Advanced, Cirrhosis Infectious, Cirrhosis Alcoholic, Cirrhosis Due to Hepatitis C
Interventions
Rosuvastatin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 75 Years
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
13
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Jun 11, 2026, 5:32 AM EDT
Recruiting No phase listed Observational

Natural History of Noncirrhotic Portal Hypertension

NCT02417740
View directory record Official record
Conditions
Cystic Fibrosis, Immunologic Deficiency Syndrome, Turner Syndrome, Congenital Hepatic Fibrosis, Idiopathic Non-Cirrhotic Portal Hypertension
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
12 Years to 100 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jun 11, 2026, 5:32 AM EDT
Completed Not applicable Interventional

Use of EL-FIT App to Promote Physical Activity

NCT04604860
View directory record Official record
Conditions
End Stage Liver DIsease, Cirrhosis, Liver
Interventions
Fitness intervention
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
40 Years to 70 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 6, 2022 · Synced Jun 11, 2026, 5:32 AM EDT
Completed Phase 2 Interventional

Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis

NCT02686762
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis, Fibrosis, Liver Diseases
Interventions
Emricasan (5 mg), Emricasan (50 mg), Placebo
Drug
Lead sponsor
Conatus Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
83
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 63 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2019 · Synced Jun 11, 2026, 5:32 AM EDT
Completed Not applicable Interventional

Exercise Versus Diet in the Treatment of Nonalcoholic Fatty Liver Disease

NCT01327443
View directory record Official record
Conditions
Non Alcoholic Fatty Liver Disease
Interventions
Weight loss, Exercise
Behavioral
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 60 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 4, 2016 · Synced Jun 11, 2026, 5:32 AM EDT
Terminated No phase listed Observational

Diagnosis and Treatment of Patients With Cystic Fibrosis

NCT00001223
View directory record Official record
Conditions
Cystic Fibrosis, Liver Disease or Abnormalities, Diabetes, Pancreatic Insufficiency (Exocrine and Endocrine)
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
4 Years to 120 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1988 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Jun 11, 2026, 5:32 AM EDT